MOTS-c: A Peptide Encoded Inside the Mitochondria

A peptide from an unexpected place

Almost every peptide in this catalog is encoded by a gene in the cell nucleus. MOTS-c is encoded inside the mitochondrial genome, specifically within the 12S rRNA region, which is part of why it drew attention when it was first described. It belongs to a small, relatively recently characterized group of mitochondrial-derived peptides, short sequences that appear to act as signals between the mitochondria and the rest of the cell.

It is 16 amino acids long. The research interest is less about the peptide's size and more about what it seems to be doing: carrying metabolic information out of the mitochondria.

The proposed mechanism

The foundational paper described MOTS-c as a regulator of metabolic homeostasis acting largely through AMPK, a master energy-sensing pathway, with skeletal muscle as a primary target tissue. In that work, MOTS-c treatment in mice was associated with resistance to age-dependent and high-fat-diet-induced insulin resistance and to diet-induced obesity (Lee et al., *Cell Metabolism* 2015). The mechanistic thread is that MOTS-c interferes with the folate cycle and downstream purine biosynthesis, which shifts the cell's energy-sensing balance toward AMPK activation.

Later work began to look at MOTS-c in humans, not as a treatment, but as a measurable molecule. One study found that circulating MOTS-c levels respond to lipids and insulin and differ in metabolic conditions such as PCOS (Ramanjaneya et al., *Clin Endocrinol* 2019), which is the kind of observational human data that tends to precede, not replace, interventional trials.

Why it's filed under longevity

The age-related angle comes from two threads in the literature: endogenous MOTS-c levels appear to decline with age, and the AMPK pathway it engages is one of the most consistently implicated systems in metabolic-aging research. That makes it a natural research tool for the field, which is different from saying anything has been demonstrated about aging outcomes.

An honest read

The interventional evidence is preclinical, concentrated in rodent and cell models. The human data so far is observational, measuring the peptide, not administering it in controlled trials. It's a compelling mechanism with an unusual origin story; it is not a settled one.

Supplied lyophilized for laboratory research use only. Not for human consumption.

References

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metab.* 2015;21(3):443–454. PubMed
2. Ramanjaneya M, et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. *Clin Endocrinol (Oxf).* 2019;91(2):278–287. PubMed